Targets for Molecular Imaging of Neuroendocrine Tumors (NETs): An Overview and Update

Area of Science:

• Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Neuroendocrine neoplasms (NENs) are a diverse tumor group with rising incidence.
• Effective diagnostic and therapeutic strategies are essential for managing NENs.
• Molecular imaging, including PET and SPECT, is vital in NEN management.

Purpose of the Study:

• To review the role of somatostatin receptor imaging in neuroendocrine tumor (NET) diagnosis and management.
• To highlight the utility of [68Ga]Ga-DOTATATE and [68Ga]Ga-DOTA-LM3.
• To discuss emerging molecular imaging targets and advanced techniques for NETs.

Main Methods:

• Review of current literature on molecular imaging in neuroendocrine neoplasms.
• Emphasis on somatostatin receptor-based radiopharmaceuticals ([68Ga]Ga-DOTATATE, [68Ga]Ga-DOTA-LM3).
• Exploration of novel targets (glucose metabolism, FAP) and dual-tracer approaches.

Main Results:

• Somatostatin receptor imaging demonstrates high sensitivity and specificity for NET diagnosis, staging, and treatment planning.
• [68Ga]Ga-DOTATATE and [68Ga]Ga-DOTA-LM3 are effective in delineating disease extent and identifying occult tumors.
• Emerging targets and advanced imaging modalities show promise for refining diagnostics and therapeutics.

Conclusions:

• Molecular imaging, particularly somatostatin receptor imaging, is indispensable for NET management.
• Novel imaging targets and integrated approaches are enhancing diagnostic accuracy and therapeutic potential.
• Continued research is vital to validate new imaging agents and techniques for improved patient outcomes.